Hypothalamic Arousal Regions Are Activated During Modafinil-induced Wakefulness

Overview

Journal J Neurosci

Specialty Neurology

Date 2000 Nov 9

PMID 11069971

Citations 126

Authors

T E Scammell

I V Estabrooke

M T McCarthy

R M Chemelli

M Yanagisawa

M S Miller

C B Saper

Affiliations

Soon will be listed here.

Abstract

Modafinil is an increasingly popular wake-promoting drug used for the treatment of narcolepsy, but its precise mechanism of action is unknown. To determine potential pathways via which modafinil acts, we administered a range of doses of modafinil to rats, recorded sleep/wake activity, and studied the pattern of neuronal activation using Fos immunohistochemistry. To contrast modafinil-induced wakefulness with spontaneous wakefulness, we administered modafinil at midnight, during the normal waking period of rats. To determine the influence of circadian phase or ambient light, we also injected modafinil at noon on a normal light/dark cycle or in constant darkness. We found that 75 mg/kg modafinil increased Fos immunoreactivity in the tuberomammillary nucleus (TMN) and in orexin (hypocretin) neurons of the perifornical area, two cell groups implicated in the regulation of wakefulness. This low dose of modafinil also increased the number of Fos-immunoreactive (Fos-IR) neurons in the lateral subdivision of the central nucleus of the amygdala. Higher doses increased the number of Fos-IR neurons in the striatum and cingulate cortex. In contrast to previous studies, modafinil did not produce statistically significant increases in Fos expression in either the suprachiasmatic nucleus or the anterior hypothalamic area. These observations suggest that modafinil may promote waking via activation of TMN and orexin neurons, two regions implicated in the promotion of normal wakefulness. Selective pharmacological activation of these hypothalamic regions may represent a novel approach to inducing wakefulness.

Citing Articles

Exploring the Literature on Narcolepsy: Insights into the Sleep Disorder That Strikes during the Day.

Matota A, Bordeianu A, Severin E, Jidovu A NeuroSci. 2024; 4(4):263-279.

PMID: 39484177 PMC: 11523731. DOI: 10.3390/neurosci4040022.

Pharmacological interventions for the treatment of obstructive sleep apnea syndrome.

Liu J, Yang X, Li G, Liu P Front Med (Lausanne). 2024; 11:1359461.

PMID: 38495117 PMC: 10943699. DOI: 10.3389/fmed.2024.1359461.

Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice.

Sakai N, Nishino S Neurotherapeutics. 2022; 20(2):546-563.

PMID: 36544071 PMC: 10121964. DOI: 10.1007/s13311-022-01328-2.

The Antinarcolepsy Drug Modafinil Reverses Hypoglycemia Unawareness and Normalizes Glucose Sensing of Orexin Neurons in Male Mice.

Patel V, Sarkar P, Siegel D, Teegala S, Hirschberg P, Wajid H Diabetes. 2022; 72(8):1144-1153.

PMID: 36525384 PMC: 10382647. DOI: 10.2337/db22-0639.

Orexin Signaling: A Complex, Multifaceted Process.

Dale N, Hoyer D, Jacobson L, Pfleger K, Johnstone E Front Cell Neurosci. 2022; 16:812359.

PMID: 35496914 PMC: 9044999. DOI: 10.3389/fncel.2022.812359.

References

Eaton M, Cheung S, Moore K, Lookingland K . Dopamine receptor-mediated regulation of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 1996; 738(1):60-6. DOI: 10.1016/0006-8993(96)00765-2. View

Lin J, Sakai K, Vanni-Mercier G, Jouvet M . A critical role of the posterior hypothalamus in the mechanisms of wakefulness determined by microinjection of muscimol in freely moving cats. Brain Res. 1989; 479(2):225-40. DOI: 10.1016/0006-8993(89)91623-5. View

Lin J, Sakai K, Jouvet M . Hypothalamo-preoptic histaminergic projections in sleep-wake control in the cat. Eur J Neurosci. 1994; 6(4):618-25. DOI: 10.1111/j.1460-9568.1994.tb00306.x. View

Johansson B, Lindstrom K, Fredholm B . Differences in the regional and cellular localization of c-fos messenger RNA induced by amphetamine, cocaine and caffeine in the rat. Neuroscience. 1994; 59(4):837-49. DOI: 10.1016/0306-4522(94)90288-7. View

Inagaki N, Yamatodani A, Tohyama M, Watanabe T, Wada H . Organization of histaminergic fibers in the rat brain. J Comp Neurol. 1988; 273(3):283-300. DOI: 10.1002/cne.902730302. View

Nishino S, Mignot E . Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997; 52(1):27-78. DOI: 10.1016/s0301-0082(96)00070-6. View

Lisk R, SAWYER C . Induction of paradoxical sleep by lights-off stimulation. Proc Soc Exp Biol Med. 1966; 123(3):664-7. DOI: 10.3181/00379727-123-31571. View

Sherin J, Elmquist J, Torrealba F, Saper C . Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J Neurosci. 1998; 18(12):4705-21. PMC: 6792696. View

Scammell T, Gerashchenko D, Urade Y, Onoe H, Saper C, HAYAISHI O . Activation of ventrolateral preoptic neurons by the somnogen prostaglandin D2. Proc Natl Acad Sci U S A. 1998; 95(13):7754-9. PMC: 22747. DOI: 10.1073/pnas.95.13.7754. View

10.

Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X . The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999; 98(3):365-76. DOI: 10.1016/s0092-8674(00)81965-0. View

11.

Hagan J, Leslie R, Patel S, Evans M, Wattam T, Holmes S . Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A. 1999; 96(19):10911-6. PMC: 17982. DOI: 10.1073/pnas.96.19.10911. View

12.

Moga M, Saper C, Gray T . Bed nucleus of the stria terminalis: cytoarchitecture, immunohistochemistry, and projection to the parabrachial nucleus in the rat. J Comp Neurol. 1989; 283(3):315-32. DOI: 10.1002/cne.902830302. View

13.

Elmquist J, Scammell T, Jacobson C, Saper C . Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. J Comp Neurol. 1996; 371(1):85-103. DOI: 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H. View

14.

Sagar S, Sharp F, Curran T . Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science. 1988; 240(4857):1328-31. DOI: 10.1126/science.3131879. View

15.

Broughton R, Fleming J, George C, Hill J, Kryger M, Moldofsky H . Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997; 49(2):444-51. DOI: 10.1212/wnl.49.2.444. View

16.

Akaoka H, Roussel B, Lin J, Chouvet G, Jouvet M . Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett. 1991; 123(1):20-2. DOI: 10.1016/0304-3940(91)90148-m. View

17.

Vanni-Mercier G, Sakai K, Jouvet M . [Specific neurons for wakefulness in the posterior hypothalamus in the cat]. C R Acad Sci III. 1984; 298(7):195-200. View

18.

Mignot E, Nishino S, Guilleminault C, Dement W . Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep. 1994; 17(5):436-7. DOI: 10.1093/sleep/17.5.436. View

19.

LaHoste G, Yu J, Marshall J . Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc Natl Acad Sci U S A. 1993; 90(16):7451-5. PMC: 47159. DOI: 10.1073/pnas.90.16.7451. View

20.

Ferraro L, Tanganelli S, OConnor W, Antonelli T, Rambert F, Fuxe K . The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett. 1996; 220(1):5-8. DOI: 10.1016/s0304-3940(96)13212-2. View